Paul G. Richardson

Also affiliated with Dana-Farber Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 40 papers. Top paper: “Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma”.

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

New England Journal of Medicine(2022)10.1056/nejmoa2204925

N/A

6.2DataRank · unranked

474 citations

Susanna Jacobus, Edie Weller, Hani Hassoun, Sagar Lonial, Noopur Raje +51 more

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30354-9

N/A

3.8DataRank · unranked

126 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Sandi Hita +12 more

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

Leukemia(2021)10.1038/s41375-021-01301-6

N/A

2.1DataRank · unranked

76 citations

Fabrizio Accardi, Teru Hideshima, Yu‐Tzu Tai, Rao Prabhala, Aaron Shambley +6 more

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

Nature Communications(2024)10.1038/s41467-024-45561-z

N/A

1.0DataRank · unranked

35 citations

Lijie Xing, Jiang Li, Kenneth Wen, Ning Liu, Yuntong Liu +17 more

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

American Journal of Hematology(2021)10.1002/ajh.26361

N/A

0.994DataRank · unranked

23 citations

Vera J. Suman, Sascha A. Tuchman, Jacob P. Laubach, Hani Hassoun, Yvonne A. Efebera +7 more

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins

Cell Reports(2021)10.1016/j.celrep.2020.108532

N/A

0.716DataRank · unranked

117 citations

Geoffrey M. Matthews, Sara Gandolfi, Ricardo De Matos Simoes, Dennis L. Buckley, Joseline Raja +34 more

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Cancer Cell(2022)10.1016/j.ccell.2022.10.017

N/A

0.626DataRank · unranked

64 citations

Michelle P. Aranha, Robert Redd, Joanna Bagińska, Nicholas J. Haradhvala, Margaret Hallisey +34 more

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Blood(2024)10.1182/blood.2024025939

N/A

0.621DataRank · unranked

10 citations

Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar +9 more

Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

Transplantation and Cellular Therapy(2020)10.1016/j.bbmt.2020.09.008

N/A

0.568DataRank · unranked

7 citations

Angela R. Smith, Nancy A. Kernan, Leslie Lehmann, Robert J. Ryan, Stephan A. Grupp +1 more

Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy

Blood Cancer Journal(2023)10.1038/s41408-023-00802-0

N/A

0.457DataRank · unranked

20 citations

Christine‐Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Shahrier Hossain +12 more

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Blood(2024)10.1182/blood.2023022777

N/A

0.457DataRank · unranked

20 citations

Eugenio Morelli, Megan Johnstone, Marcello Turi, Mehmet Samur, Cirino Botta +24 more

Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse

Blood Advances(2024)10.1182/bloodadvances.2024013623

N/A

0.372DataRank · unranked

5 citations

Vera J. Suman, Yvonne A. Efebera, Noopur Raje, Sascha A. Tuchman, Cesar Rodriguez Valdes +7 more

Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival

Frontiers in Oncology(2023)10.3389/fonc.2023.1271807

N/A

0.360DataRank · unranked

10 citations

William E. Pierceall, Mehmet Samur, Lakshmi B. Potluri, Kevin Hong, Teresa Peluso +18 more

Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma

Biology of Blood and Marrow Transplantation(2020)10.1016/j.bbmt.2020.03.028

N/A

0.351DataRank · unranked

6 citations

Vera J. Suman, Kouros Owzar, Katelyn Santo, Don M. Benson, Thomas C. Shea +10 more

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

medRxiv(2024)10.1101/2024.04.19.24306082

N/A

0.343DataRank · unranked

6 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.8016

N/A

0.165DataRank · unranked

2 citations

Hannah Seah, Vaishnavi Reddy Bade, Arthur Krogman, Shree Acharya, Andreea Negroiu +13 more

Biological correlates to support a clinical role for tagraxofusp, a novel targeted therapy directed to CD123, in combination with pomalidomide and dexamethasone, to target plasmacytoid dendritic cells in poor-risk patients with multiple myeloma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e20537

N/A

0.104DataRank · unranked

1 citations

Arghya Ray, Yan Song, Arturo Olguin, Janice Chen, Christopher Brooks +4 more

Data from Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias

(2023)10.1158/1078-0432.c.6517722

N/A

0DataRank · unranked

0 citations

Cécile Rouleau, Cinara Echart, Krishna Menon, Beverly A. Teicher, Maria Distaso +6 more

Data from Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias

(2023)10.1158/1078-0432.c.6517722.v1

N/A

0DataRank · unranked

0 citations

Cécile Rouleau, Cinara Echart, Krishna Menon, Beverly A. Teicher, Maria Distaso +6 more

Data from The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

(2023)10.1158/1078-0432.c.6517504.v1

N/A

0DataRank · unranked

0 citations

Teru Hideshima, Mariateresa Fulciniti, Robert J. Lutz, Hiroshi Yasui, Yutaka Okawa +16 more

Data from Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation

(2023)10.1158/2643-3230.c.6550306

N/A

0DataRank · unranked

0 citations

Eugenio Morelli, Mehmet Samur, Cirino Botta, Teru Hideshima, Giada Bianchi +13 more

Self-Reported Financial Difficulties Among Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia Treated at U.S. Community Oncology Clinics (Alliance A231602CD)

medRxiv(2024)10.1101/2024.09.13.24311098

N/A

0DataRank · unranked

1 citations

Shaylene McCue, Travis Dockter, Heather Gunn, Stacie B. Dusetzina, Antonia V. Bennett +12 more

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

Journal of Clinical Oncology(2020)10.1200/jco.20.00437

N/A

0DataRank · unranked

182 citations

Romanos Sklavenitis‐Pistofidis, Jihye Park, Robert Redd, Benny Zhitomirsky, Andrew Dunford +31 more

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nature Communications(2025)10.1038/s41467-024-55308-5

N/A

0DataRank · unranked

14 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?

British Journal of Haematology(2020)10.1111/bjh.16764

N/A

0DataRank · unranked

33 citations

Clifton C. Mo, Ola Landgren, Paul G. Richardson, Dickran Kazandjian

Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients

Biology of Blood and Marrow Transplantation(2020)10.1016/j.bbmt.2020.03.011

N/A

0DataRank · unranked

29 citations

Nancy A. Kernan, Antonio Pagliuca, Robert J. Ryan, William Tappe, Paul G. Richardson +1 more

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)

eScholarship (California Digital Library)(2020)10.17615/m2r7-rg29

N/A

0DataRank · unranked

28 citations

Ian Frank, Susan H. Eshleman, Ken Ho, Robert A. Salata, Jorge Santana +24 more

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.18_suppl.lba3

N/A

0DataRank · unranked

31 citations

Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina A. Singh +15 more

Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8507

N/A

0DataRank · unranked

26 citations

Sikander Ailawadhi, Rachael Sexton, Antje Hoering, Brea Lipe, Sandi Hita +9 more

Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local–Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082

Carolina Digital Repository (University of North Carolina at Chapel Hill)(2020)10.17615/pdfa-n953

N/A

0DataRank · unranked

0 citations

Thomas J. FitzGerald, William P. Peters, F. Laurie, Steven L. Seagren, Jinli Ma +13 more

Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation

Blood Cancer Discovery(2021)10.1158/2643-3230.bcd-21-0047

N/A

0DataRank · unranked

139 citations

Eugenio Morelli, Mehmet Samur, Cirino Botta, Teru Hideshima, Giada Bianchi +13 more

A clinical perspective on plasma cell leukemia; current status and future directions

Blood Cancer Journal(2021)10.1038/s41408-021-00414-6

N/A

0DataRank · unranked

60 citations

Leona Holmberg, Omar Nadeem, Paul G. Richardson, Sherilyn A. Tuazon

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment

Science Advances(2021)10.1126/sciadv.abg2697

N/A

0DataRank · unranked

26 citations

Teru Hideshima, Lijie Xing, Su Wang, Wenrong Zhou, Mehmet Samur +15 more

Assessing financial difficulty in patients with multiple myeloma: Preliminary results of ALLIANCE A231602CD.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8031

N/A

0DataRank · unranked

0 citations

Shaylene McCue, Travis Dockter, Bruce D. Rapkin, Stacie B. Dusetzina, Antonia V. Bennett +8 more

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Blood Cancer Journal(2022)10.1038/s41408-022-00695-5

N/A

0DataRank · unranked

61 citations

Lawrence Baizer, Natalie S. Callander, Sergio Giralt, Jens Hillengaß, Boris Freidlin +11 more

Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.8054

N/A

0DataRank · unranked

4 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Jason Valent +11 more

Self-reported financial difficulties among patients with multiple myeloma and chronic lymphocytic leukemia: An Alliance for Clinical Trials in Oncology study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6602

N/A

0DataRank · unranked

1 citations

Shaylene McCue, Travis Dockter, Stacie B. Dusetzina, Bruce D. Rapkin, Elisa S. Weiss +3 more

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Blood(2023)10.1182/blood.2022017094

N/A

0DataRank · unranked

48 citations

Marco Roncador, Anıl Aktaş Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphaël Szalat +14 more

Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma

JCI Insight(2023)10.1172/jci.insight.159924

N/A

0DataRank · unranked

15 citations

Dana Cholujová, Gábor Beke, Teru Hideshima, Lubos Klucar, Merav Leiba +6 more

Data from The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

(2023)10.1158/1078-0432.c.6517504

N/A

0DataRank · unranked

0 citations

Teru Hideshima, Mariateresa Fulciniti, Robert J. Lutz, Hiroshi Yasui, Yutaka Okawa +16 more